Tandem Diabetes Care (Nasdaq:TNDM) announced that it made its t:slim X2 insulin pump available with the Dexcom (Nasdaq:DXCM) ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to invest in for the next 2 years. On April 30, DexCom reported Q1 ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom posted better-than-expected Q1 2026 results, with revenue up 15% year-over-year on strong uptake of its G7 continuous glucose monitor and expanded coverage for type 2 diabetes patients not ...

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required. In ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest ...

DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.

DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people ...